{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:29:14Z","timestamp":1791088154125,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,7,16]],"date-time":"2001-07-16T00:00:00Z","timestamp":995241600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dyskinesia, secondary to dopamine replacement therapy, is the major complication of currently available therapies for Parkinson's disease. Alpha<jats:sub>2<\/jats:sub> adrenoceptor antagonists, such as idazoxan, can significantly reduce levodopa\u2010induced dyskinesia in the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2010lesioned, nonhuman primate model of Parkinson's disease and in human. This action of adrenoceptor antagonists may involve blockade of the actions of noradrenaline synthesised from levodopa. We hypothesise that, because dopamine receptor agonists, such as apomorphine, cannot be metabolised to produce noradrenaline, activation of adrenoceptors may not be involved in dyskinesia produced by such agents. If this were the case, idazoxan would not be expected to reduce apomorphine\u2010induced dyskinesia.<\/jats:p><jats:p>MPTP\u2010lesioned marmosets with stable dyskinesia induced by prolonged levodopa therapy were given an acute challenge with apomorphine (0.3 mg\/kg s.c.) or levodopa (8.0 mg\/kg p.o.), these doses produced equivalent peak\u2010dose dyskinesia. Idazoxan (2.5 mg\/kg p.o.), or vehicle, was then administered with either apomorphine or levodopa. Idazoxan abolished levodopa\u2010induced dyskinesia but did not affect apomorphine\u2010induced dyskinesia (<jats:italic>P<\/jats:italic> &lt; 0.05 and <jats:italic>P<\/jats:italic> &gt; 0.05, respectively, Wilcoxon matched pairs test). Idazoxan also extended the anti\u2010parkinsonian actions of levodopa but did not affect those of apomorphine.<\/jats:p><jats:p>The pharmacological characteristics of the neural mechanisms underlying levodopa\u2010induced dyskinesia and apomorphine\u2010induced dyskinesia in parkinsonism thus appear to be distinct, at least with respect to the involvement of alpha<jats:sub>2<\/jats:sub> adrenoceptors. Specifically, levodopa, but not apomorphine\u2010induced dyskinesia, involves activation of adrenoceptors. This finding may have major implications for understanding dyskinesia and should be borne in mind when designing clinical studies in which levodopa or dopamine receptor agonist challenges are employed to assess potential anti\u2010dyskinetic properties of drugs. \u00a9 2001 Movement Disorder Society.<\/jats:p>","DOI":"10.1002\/mds.1148","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T14:54:07Z","timestamp":1030287247000},"page":"642-650","source":"Crossref","is-referenced-by-count":72,"title":["Neural mechanisms underlying peak\u2010dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha<sub>2<\/sub> adrenoceptor antagonist idazoxan"],"prefix":"10.1002","volume":"16","author":[{"given":"Susan H.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1996.6380"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.10.1855"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1323"},{"key":"e_1_2_6_8_2","first-page":"71","article-title":"Advances in understanding the neural mechanisms underlying L\u2010DOPA\u2010induced dyskinesia","volume":"80","author":"Brotchie JM","year":"1999","journal-title":"Adv Neurol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_6_10_2","first-page":"152","article-title":"Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP\u2010induced parkinsonism","volume":"547","author":"Filion M","year":"1991","journal-title":"Brain Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/115.3.809"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)00484-M"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199911)46:5<732::AID-ANA8>3.0.CO;2-Q"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(91)90106-T"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199310000-00004"},{"issue":"1","key":"e_1_2_6_17_2","first-page":"116","article-title":"A pilot study of idazoxan, an alpha2 antagonist, in Parkinson's disease","volume":"11","author":"Peyro\u2010Saint\u2010Paul H","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_6_18_2","first-page":"111","article-title":"L\u2010DOPA\u2010induced dyskinesias improvement by an \u03b12 antagonist, idazoxan, in patients with Parkinson's disease","volume":"12","author":"Rascol O","year":"1997","journal-title":"Mov Disord"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(84)90030-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(94)90386-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19960812)372:1<135::AID-CNE9>3.0.CO;2-4"},{"key":"e_1_2_6_22_2","first-page":"586.1","article-title":"Coexistence of \u03b12C\u2010adrenoceptor immunoreactivity with GABA, calbindin D28K and parvalbumin immunoreactivity in rat striatal neurons","volume":"23","author":"Kulatunga M","year":"1997","journal-title":"Soc Neurosci"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00260-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91416-1"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870070204"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090103"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498258809041689"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245739"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100041500","article-title":"Levodopa\u2010induced dyskinesia:facts and fancy. What dose the MPTP monkey model tell us?","volume":"19","author":"Bedard PJ","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_6_31_2","first-page":"103","article-title":"DOPA\u2010induced \u201cpeak dose\u201d dyskinesia: clues implicating D2 receptor\u2010mediated mechanisms using dopaminergic agonists in MPTP monkeys","volume":"45","author":"Blanchet PJ","year":"1995","journal-title":"J Neural Transm"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.573-b"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91531-E"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.11.1004"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.11.1723"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(83)90097-7"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702943"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701214"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90624-5"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900167"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(76)90217-3"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00499922"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01255820"},{"key":"e_1_2_6_44_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-3565(24)38022-X","article-title":"Effects of alpha\u20102 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6\u2010hydroxydopaminutee lesions of the nigrostriatal pathway","volume":"288","author":"Chopin P","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(76)90093-9"},{"key":"e_1_2_6_46_2","first-page":"525","article-title":"L\u2010threo\u20103, 4\u2010dihydroxyphenylserine treatment of Parkinson's disease","volume":"16","author":"Ogawa N","year":"1985","journal-title":"J Med"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.1148","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.1148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:04:52Z","timestamp":1760958292000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.1148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1002\/mds.1148"],"URL":"https:\/\/doi.org\/10.1002\/mds.1148","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}